Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

Rhea-AI Summary

Kala Pharmaceuticals (NASDAQ:KALA) has rescheduled its financial results conference call to report Q3 2021 results on November 15 at 10:30 AM ET. The call will provide a business update, with access available via dial-in or a live webcast on the company's investor site. Kala focuses on innovative therapies for eye diseases, featuring products like EYSUVIS and INVELTYS, utilizing the AMPPLIFY Drug Delivery Technology. For further details, visit their website.

Positive

• Commercial-stage biopharmaceutical company with innovative therapies for eye diseases.
• Utilizes AMPPLIFY Drug Delivery Technology, enhancing drug efficacy.
• Current products include EYSUVIS and INVELTYS, addressing significant market needs.

Negative

• None.

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of its previously scheduled financial results conference call and live audio webcast. The Company will now report its third quarter 2021 financial results and provide a business update on Monday, November 15^th at 10:30 am. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7298039. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investor” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

When will Kala Pharmaceuticals report its Q3 2021 financial results?

Kala Pharmaceuticals will report its Q3 2021 financial results on November 15, 2021, at 10:30 AM ET.

How can I access Kala Pharmaceuticals' financial results conference call?

You can access the conference call by dialing 866-300-4091 for domestic calls or 703-736-7433 for international calls using conference ID 7298039.

What products does Kala Pharmaceuticals offer?

Kala Pharmaceuticals offers EYSUVIS and INVELTYS, both of which use their AMPPLIFY Drug Delivery Technology for treating eye diseases.